Just in:
PolyU forms global partnership with ZEISS Vision Care to expand impact and accelerate market penetration of patented myopia control technology // Forward Fashion’s Artelli Presents: Nobuyoshi Araki’s “Paradise” Starting from April 27th, at K11 MUSEA // Moomoo Wins “Digital CX Awards 2024” by The Digital Banker // Andertoons by Mark Anderson for Fri, 26 Apr 2024 // Abu Dhabi Secures US$5 Billion in Fresh Funding // Etihad Airways Announces Paris Service with A380 // DIFC Courts Cement Role as Top English Dispute Resolution Choice // CapBridge Shares Insights on the Recent Launch of Digital Asset ETFs in Hong Kong // Ministry of Agriculture Supports Taiwanese Tea’s Entry into Singapore Market to Boost Global Presence // Abu Dhabi Unveils Online Portal to Strengthen Healthcare Workforce // Nano-Care Deutschland AG launches next generation of sustainable PFAS-free oleophobic coatings // ByteDance Eyes US Shutdown for TikTok // World Football Federation Secures Sponsorship From Saudi Oil Giant // Emirates to Embrace Electric Seaglider Travel // World Intellectual Property Day: OPPO Maintains Top 10 Global IP Ranking for Fifth Consecutive Year // UN Commends Vietnam’s Progress on Climate Goals // Oman Seeks Growth Through Strategic Economic Alliances // GE Jun, Chairman and CEO of TOJOY, Delivers an Inspiring Speech: “Leaping Ahead Again” // Prince Holding Group’s Chen Zhi Scholarship Clinches Silver Stevie for CSR Excellence at Asia-Pacific Stevie Awards // TPBank and Backbase Clinch ‘Best Omni-Channel Digital CX Solution’ at the Digital CX Awards 2024 //

Ethicists Say Go Slow On Gene-editing CRISPR, Ponder What It Means To Be Human

ADVERTISEMENT

The search for cure of congenital and other serious illnesses may be over with the revolutionary gene-editing tool known as CRISPR. Among its uses is to help scientists understand the genetic origin of an illness, which was not possible in the past.

The future, the scientific community trumpeted, has arrived.

Ethicists warned, however, of the risks as scientists wield the tool that has the potential not only to cure patient’s congenital disease but could also make permanent changes in the human genome that are heritable by a person’s offspring.

In a report by the National Academy of Sciences and the National Academy of Medicine published on Feb. 14, the experts sounded the need not to rush on CRISPR. While the report did not completely prohibit the editing of a human genome, it called for sort of bar of standards to allow it only if proven safe.

Major Departure, A Slippery Slope

The recent report penned by some 22 experts from different countries was viewed as a major departure from the previous stand on CRISPR. Some ethicists viewed it a slippery slope.

In December 2015, the National Academy of Sciences, at the end of the gene-editing summit, endorsed for some basic research to proceed but put a brake on the use of genetically modified germline to establish pregnancy.

The latest report had taken a more open position provided that the interventions should meet several criteria which include the following: it should be proven safe, and it should be regulated to be used only to cure rare and serious illnesses.

“We’re talking only about fixing diseases,” MIT biologist Richard Hynes, one of the leaders of the new study, said.

Ethicists agree that therapeutic uses of the gene-editing tool are acceptable. It has, however, become a slippery slope when CRISPR is used for cosmetic changes. For example, the color of the eyes or desired athletic trait. The technique’s potential use to make changes in sperm and eggs or embryo, which will be permanent and heritable by future generations, raises the fear of eugenic-driven human population.

Ethicists, one of them is Alta Charo, a professor of law and bioethics at the University of Wisconsin, protested saying the criteria along the slippery road is numerous.

Several studies conducted on the new technique are “not even close to the amount of research that we need before you can move forward,” Charo said.

‘What It Means To Be Human’

Jennifer Doudna, the scientist who helped developed the revolutionary gene-editing technique, pondered on the consequences of CRISPR.



Doudna raised the question of “What it means to be human” after her encounter with a mother whose son has Down syndrome.

“There’s something about him that’s so special. He’s so loving in a way that’s unique to him. I wouldn’t change it,” the mother told Doudna.

CRISPR, which stands for clustered regularly interspaced short palindromic repeats, is not the first in DNA editing techniques.

Other techniques include Zinc Finger Nucleases (ZFNs), and Transcription activator-like effector nucleases (TALENs).

Much interest has been drawn by Doudna’s CRISPR because it is easy, cost-effective, and efficient.

The technology is far from being perfect and questions are many. With its controversial potential uses in editing human genome, many ask: How far should science go in tinkering with human life?

© 2017 Tech Times, All rights reserved. Do not reproduce without permission.

(Via TechTimes)

ADVERTISEMENT

ADVERTISEMENT
Just in:
TPBank and Backbase Clinch ‘Best Omni-Channel Digital CX Solution’ at the Digital CX Awards 2024 // Galaxy Macau’s Sakura Cultural Festival Kicked off in Splendor // Liverpool FC continues international growth with first official retail partnership in South Korea // Andertoons by Mark Anderson for Fri, 26 Apr 2024 // NetApp’s 2024 Cloud Complexity Report Reveals AI Disrupt or Die Era Unfolding Globally // Abu Dhabi Secures US$5 Billion in Fresh Funding // Andertoons by Mark Anderson for Thu, 25 Apr 2024 // Emirates to Embrace Electric Seaglider Travel // Downpours in Oman and UAE Likely Amplified by Warming Planet // World Football Federation Secures Sponsorship From Saudi Oil Giant // Etihad Airways Announces Paris Service with A380 // Ministry of Agriculture Supports Taiwanese Tea’s Entry into Singapore Market to Boost Global Presence // GE Jun, Chairman and CEO of TOJOY, Delivers an Inspiring Speech: “Leaping Ahead Again” // Forward Fashion’s Artelli Presents: Nobuyoshi Araki’s “Paradise” Starting from April 27th, at K11 MUSEA // PolyU forms global partnership with ZEISS Vision Care to expand impact and accelerate market penetration of patented myopia control technology // AVPN Charts Path Forward at 2024 Global Conference // Prince Holding Group’s Chen Zhi Scholarship Clinches Silver Stevie for CSR Excellence at Asia-Pacific Stevie Awards // Abu Dhabi Unveils Online Portal to Strengthen Healthcare Workforce // e& UAE Unveils Strategic Roadmap // Nano-Care Deutschland AG launches next generation of sustainable PFAS-free oleophobic coatings //